Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice by Goudy, Kevin S. et al.
Gene gun-mediated DNA vaccination enhances antigen-specific
immunotherapy at a late preclinical stage of type 1 diabetes in
nonobese diabetic mice
Kevin S. Goudy1, Bo Wang1, and Roland Tisch1
1Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, NC 27599-7020
Abstract
Type 1 diabetes (T1D) is characterized by the T cell mediated destruction of the insulin producing
β cells. Antigen-specific immunotherapies are used to selectively tolerize β cell-specific pathogenic
T cells either directly, or indirectly through the induction of immunoregulatory T cells. A key concern
of antigen-specific immunotherapy is exacerbating autoimmunity. We compared the T cell reactivity
and efficacy induced by plasmid DNA (pDNA) encoding glutamic acid decarboxylase 65 (GAD65)
administered via intramuscular versus gene gun vaccination in NOD mice at a late preclinical stage
of T1D. Whereas intramuscular injection of pGAD65 promoted a predominant type 1 CD4+ T cell
response and failed to suppress ongoing β cell autoimmunity, gene gun vaccination preferentially
induced IL-4 secreting CD4+ T cells and significantly delayed the onset of diabetes. These findings
demonstrate that gene gun delivery of autoantigen-encoding pDNA preferentially elicits
immunoregulatory T cells and offers a safe, effective mode of pDNA vaccination for the treatment
of T1D and other autoimmune diseases.
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INTRODUCTION
Type 1 diabetes (T1D) is caused by the autoimmune-mediated destruction of the insulin-
producing β cells of the islets of Langerhans [1]. Based on studies in the nonobese diabetic
(NOD) mouse, a spontaneous model of T1D, the primary effectors of β cell destruction are
CD4+ and CD8+ T cells [2;3]. Pathogenic effector T cells typically exhibit a type 1 phenotype,
and target a number of β cell autoantigens including proinsulin, insulin, islet-specific
glucose-6-phosphatase catalytic subunit related protein (IGRP), and glutamic acid
decarboxylase 65 (GAD65) [4;5;6;7;8]. The critical events associated with the development
and expansion of these type 1 β cell-specific effector T cells remain ill-defined, although
aberrant peripheral tolerance is believed to contribute. For example, insufficient numbers of
IL-4 secreting type 2 T cells or IL-10 secreting Tr1 cells, and defective development and/or
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function of FoxP3-expressing immunoregulatory T cells (Treg) have been reported in NOD
mice and diabetic patients [9;10;11;12;13].
A variety of immunotherapies have been developed to reestablish the functional balance
between pathogenic and immunoregulatory T cells and prevent and/or treat T1D [14;15].
Antigen-specific immunotherapy is one such strategy to induce β cell-specific
immunoregulatory T cells and selectively block the initiation and/or progression of β cell
autoimmunity [16;17;18;19]. The efficacy of the approach is largely dependent on the
frequency of immunoregulatory T cells induced upon administration of a given β cell
autoantigen versus induction and/or expansion of pathogenic T cells. The conditions to
preferentially elicit immunoregulatory T cells in an antigen-specific manner become more
stringent at late preclinical or clinical stages of T1D when β cell autoimmunity is well
established [20;21].
We and others have successfully used plasmid DNA (pDNA)-based vaccines to induce β cell-
specific immunoregulatory CD4+ T cells, and in turn prevent and suppress β cell autoimmunity
in NOD mice [22;23;24;25;26;27;28;29;30;31]. In general, pDNA offer: i) a relatively facile
approach for vaccination, overcoming the need to produce and store antigen, and ii) an
opportunity to readily manipulate the nature of the induced immune response [32]. Studies
using NOD mice have delivered β cell autoantigen-encoding pDNA prepared in saline via
intramuscular (i.m.) [26;28;29;30] and intradermal (i.d.) needle injection [25], or via oral
administration [25;31]. Typically, effective prevention of diabetes has been dependent on co-
injection of pDNA encoding anti-inflammatory cytokines such as IL-4 and/or IL-10, especially
once β cell autoimmunity is well established [26;28;29;30;31]. Indeed, i.m. injection of pDNA
encoding antigen-only has had either no immunotherapeutic effect or worse, elicited β cell-
specific type 1 CD4+ T effectors [29;30]. The current study was initiated to determine how the
mode of delivery affects the efficacy of pDNA to prevent diabetes at a late preclinical stage in
NOD mice. Specifically, the nature of the T cell response and immunotherapeutic efficacy of
pDNA encoding a fragment of murine GAD65 fused to human immunoglobulin Fc (pGAD65)
administered by i.m. versus gene gun vaccination were compared. Gene gun vaccination entails
bombardment of the upper most layers of the skin with pDNA-coated particles[32;33]. Notably,
studies have shown that gene gun immunization preferentially induces type 2 T effectors
[34;35]. With this in mind, we tested the hypothesis that gene gun vaccination of pGAD65-
only is more effective at eliciting GAD65-specific immunoregulatory T cells and suppressing
ongoing β cell autoimmunity than i.m. injection of pGAD65 prepared in saline.
MATERIALS AND METHODS
Mice
NOD/LtJ, NOD.il4tm1Cgn (NOD.IL-4null), and NOD.scid mice were purchased from Jackson
Laboratory (Bar Harbor, MA) and bred under specific pathogen-free conditions. All
experiments with mice were approved by the University of North Carolina at Chapel Hill
Institutional Animal Care and Use Committee.
pDNA vaccination
pDNA encoding human immunoglobulin Fc (IgFc) fusion molecules consisting of a fragment
of murine GAD65 (pGAD65) or hen egg lysozyme (pHEL) spanning nucleotides 656–1070
and 175–270, respectively, have previously been described [29]. The Jw4303 vector backbone
contains two CpG motifs [30]. pDNA was prepared from DH5. Escherichia coli using a Qiagen
endotoxin-free kit (Qiagen, Valencia, CA). For i.m. injection, pDNA was resuspended at 1.0
mg/ml in calcium-free PBS, and NOD mice received four i.m. injections of 50 ul (50 µg) of
pDNA in each hind quadricep muscle over 28 days with an insulin syringe. Biolistic delivery
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of pDNA was carried out using a Helios gene gun (Bio-Rad, Hercules, CA) and 1.6 µM gold
particles (Bio-Rad). Gold particles (0.5 mg) were coated with 1 µg of pDNA using 1 mM
CaCl2 and 0.05 mM spermidine (Sigma, St. Louis, MO). The efficiency of coating was assessed
by eluting pDNA off the gold particles in Tris-EDTA buffer and then quantitating pDNA via
agarose gel electrophoresis and spectrophotometry (Beckman Coulter, Fullerton, CA). NOD
mice with shaven abdomens received four shots at 1-week intervals at a helium pulse of 425
pounds per square inch.
In other experiments pDNA encoding a luciferase gene (pLUC) driven by a CMV/CB promoter
[36] was administered via gene gun or i.m. injection as described above. In vivo
bioluminescence was measured by injecting mice intraperitoneally (i.p.) with 5 mg of luciferin
(Promega, Madison, WI) and using a two-photon Xenogen imaging system (Xenogen,
Alameda, CA) while mice were under isofluorane anesthesia. The intensity of bioluminescence
was measured at the site of injection as the number of photons per second per centimeter
squared per steradian as determined by the Xenogen software and reperesented as relative optic
intensity (ROI) units.
GAD65-IgFc ELISA
Serum levels of GAD65-IgFc were measured using a human IgG ELISA kit as per the
manufacturer’s recommendations (Bethyl Laboratories, Montgomery, TX). Briefly, the
capture antibody was incubated for 45 minutes in PBS on a 96-well high-binding plate
(Corning, Lowell, MA) at room temperature. The plate was blocked with 1% bovine serum
albumin (BSA)/PBS, washed, and 25 ul of serum diluted 1:3 with 1% bovine serum albumin/
PBS was added to each well in duplicate. Samples were incubated at room temperature for 2
hours followed by washing three times. Detection antibody was then added and incubated at
room temperature for 1 hour. The plate was washed and developed using substrate A and
substrate B (BD Pharmingen, San Francisco, CA); the reaction was stopped using 4N
phosphoric acid (Sigma, St. Louis, MO). Optical density values were determined at 450 nm
wavelength using an ELISA plate reader (Molecular Devices, Sunnyvale, CA.)
Assessment of diabetes and insulitis
NOD mice were monitored weekly for the development of glycosuria via Diastix (Ames,
Elkhart, IN). Diabetes was diagnosed by 2 consecutive positive measurements over 48 hours.
Insulitis was assessed by histology. Pancreata were prepared for histology by fixation in neutral
buffered formalin followed by paraffin embedding. A minimum of five sections, 90 µm apart,
were cut from each block, stained with hematoxylin and eosin (H&E), and viewed by light
microscopy. A minimum of 40 islets were scored for each animal. The severity of insulitis was
scored as either peri-insulitis (islets surrounded by an infiltrate) or intra-insulitis (< or >50%
infiltration of the islets).
Flow cytometry
Antibodies specific for murine CD3 (2c11), CD4 (GK1.5), and CD25 (PC61) (eBiosience, San
Diego, CA) were used to stain splenocytes, inguinal lymph nodes and pancreatic lymph nodes
at 1:500 dilution. Staining with anti-FoxP3 (FJK-16s) and isotype control (IgG2a) antibody
(eBioscience, San Diego, CA) was done according to manufacturer’s recommendations at a
1:400 dilution. Acquisition of samples was performed on a 3-laser Cyan and analyzed using
Summit software build 4.3 (DAKO, Ft. Collins, CO).
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Peptides were synthesized using standard F-moc chemistry on a Rainin Symphony (Rainin
Instruments, Woburn, MA) at the peptide synthesis facility of University of North Carolina.
The purity of the peptides was verified by reverse phase HPLC and mass spectroscopy.
ELISPOT
ELISPOT was carried out as previously described [26]. Briefly, ImmunoSpot M200 plates
(Millipore, Billerica, MA) were coated overnight at 4°C with either 2 µg/ml anti-IL-5, -IL-10,
or -IFNγ and 1 µg/ml anti-IL-4 (BD PharMingen, San Jose, CA) prepared in PBS, and then
blocked with 1% BSA-PBS for a minimum of 1 hour at room temperature. Splenocytes
suspensions prepared from individual mice were plated at 1×106 cells/well. Inguinal and
pancreatic lymph nodes of 5 mice from each treatment group were harvested, pooled and
cultured overnight in the presence of 4 ng/ml of mIL-2 (Peprotech, Rocky Hill, NJ) then washed
and plated at 2×105 with an equal number of irradiated splenocytes. Peptide was added in
duplicate to wells at a final concentration of 40 µg/ml. The plates were incubated for 48 hours
at 37°C in 5.5% CO2 and then washed. Biotinylated anti-IL-4, -IL-5, -IL-10 or -IFNγ (BD
PharMingen, San Jose, CA) were added at 2 µg/ml, in 1% BSA-PBS and plates incubated
overnight at 4°C. Plates were washed and incubated with streptavidin-HRP (BD PharMingen;
1/1000) for 2 hours at room temperature. This was followed by three washes with 0.025%
Tween 20-PBS and three washes with PBS only. Development solution consisted of 0.8 ml of
3-amino-9-ethyl-carbazole (Sigma, St. Louis, MO) added to 24 ml of 0.1 M sodium acetate
(pH 5.0), plus 0.12 ml of 3.0% hydrogen peroxide; 0.2 ml was added per well.
Adoptive transfer
CD4+ T cells were isolated from splenocytes of gene gun treated NOD and NOD.IL-4null
female mice using a CD4 enrichment kit (BD Pharmingen, San Jose, CA), and resuspended at
20×106/ml in PBS. In addition, splenocytes were harvested from diabetic NOD female mice,
red blood cells lysed and the cells resuspended in PBS at 20×106/ml. NOD.scid male mice then
received i.p. injections of 8×106 diabetogenic splenocytes alone or in combination with
2×106 CD4+ T cells isolated from treated NOD or NOD.IL-4null donor mice.
RESULTS
Gene gun or i.m. delivery of pGAD65 yield high systemic levels of transgene expression
The type of immune response induced by pDNA vaccination is dependent on both the site and
mode of delivery [27;32;33]. The first set of experiments was aimed to determine the levels
and localization of transgene expression of pDNA delivered to the skin via gene gun and the
muscle via needle injection. Under the gene gun parameters employed, the 1.6 µm gold particles
were delivered to the dermal layer of the skin (Fig. 1A). To initially evaluate the duration and
level of transgene expression, pLUC which encodes luciferase was delivered once to the
abdomen (1 µg) or quadriceps (50 µg) of NOD mice via gene gun or i.m. injection, respectively,
and bioluminescence measured at the site of delivery over a 2 week period. The kinetics of
bioluminescence after a single vaccination were similar between the 2 treatment groups;
luciferase expression was readily detected after 24 hours and persisted up to 14 days post-
treatment (Fig. 1B). However, despite a 50-fold difference in the amount of pLUC
administered, up to an ~3-fold increase in the intensity of bioluminescence was detected in
NOD mice receiving pLUC delivered via gene gun versus i.m. injection (Fig. 1B).
The serum level of GAD65-IgFc protein in NOD mice receiving pGAD65 via gene gun versus
i.m. injection was compared. Here, pGAD65 was administered under treatment conditions used
to prevent diabetes (see below). Namely, NOD mice received a total of 4 injections over 4
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weeks of: i) 50 µg of pGAD65 delivered i.m. to each quadricep, or ii) gold-particles coated
with a total of 1 µg of pGAD65 to the abdomen. Note that the treatment protocol for i.m.
injection of pGAD65 was established in a previous study [29].The concentration of GAD65-
IgFc in serum was then measured over time by ELISA specific for human IgFc. Significant
levels of GAD65-IgFc (e.g. 2–3 ng/ml) were detected 7 days after the initial treatment in both
experimental groups (Fig. 1C). Notably, an ~3-fold increase in GAD65-IgFc was detected at
later time points in NOD mice receiving pGAD65 via gene gun versus i.m. injection (Fig. 1C).
Together these findings demonstrate that although robust and persistent transgene expression
is induced by i.m. injected pDNA, gene gun delivered pDNA results in enhanced and more
efficient transgene expression.
Gene gun but not i.m. delivered pGAD65 prevents diabetes in NOD mice with ongoing β cell
autoimmunity
The immunotherapeutic efficacy of gene gun versus i.m. vaccination of pGAD65 was assessed.
Ten week-old NOD female mice were treated as above and diabetes monitored up to 36 weeks
of age. At 10 weeks of age, NOD female mice are typically euglycemic yet β cell autoimmunity
is well established. The majority of NOD female mice receiving control pHEL via gene gun
(8/10) and i.m. injection (7/10) or left untreated (9/10) developed overt diabetes with no
significant difference in the time of diabetes onset (Fig. 2A). Furthermore, all NOD female
mice treated with pGAD65 via i.m. injection (10/10) developed diabetes (Fig. 2A). On the
other hand, significant protection was detected in NOD female mice receiving gene gun
delivered pGAD65 versus i.m. injected pGAD65 or the respective control groups (P≤ 0.005;
Kaplan-Meier Log Rank Test). In addition, a significant reduction in the frequency of diabetes
was detected in NOD female mice receiving gene gun (5/10) versus i.m. (10/10) delivered
pGAD65 (P=0.039; Chi Square) (Fig. 2A). Histological analysis of the nondiabetic 36 week-
old NOD female mice demonstrated that the majority of islets were infiltrated in the pGAD65
gene gun delivered group, but that the frequency of “severe” intra-insulitis (e.g. >50% intra-
insulitis) was significantly reduced compared to pHEL gene gun vaccinated or untreated NOD
mice (P<10−3, Chi-Square) (Fig. 2B). No correlation was observed between the serum levels
of GAD65-IgFc measured over time and protection against diabetes in the NOD female mice
treated with gene gun delivered pGAD65 (Fig. 2C,D). In summary, these results demonstrate
that gene gun but not i.m. vaccination of pGAD65 prevents diabetes at a late preclinical stage
of T1D, and that protection is independent of systemic levels of GAD65-IgFc.
Protection mediated by gene gun delivery of pGAD65 correlates with the induction of type 2
GAD65-specific T cells
The magnitude and nature of GAD65-specific T cell reactivity elicited by gene gun versus i.m.
injection of pGAD65 were compared. Groups of five 10-week old NOD female mice were
vaccinated with pGAD65 as described above or left untreated, and 3 weeks after the final
treatment the frequency of IL-4, IL-5, IL-10 and IFNγ secreting T cells in response to the
IAg7-restricted GAD65 peptides spanning amino acid residues 206–220 (p206), p217–236
(p217) and p290–309 (p290) was measured via ELISPOT. These three peptides are the
immunodominant epitopes found within the fragment of GAD65 encoded by pGAD65. T cell
reactivity was assessed in the: i) pancreatic lymph nodes (PLN) which drain the pancreas, ii)
inguinal lymph nodes (ILN) which drain the abdominal site of gene gun delivered pGAD65,
and iii) the spleen. A typical type 1-like response was detected in NOD female mice treated
i.m. with pGAD65 (Fig. 3). Namely a significant increase in the frequency of IFNγ secreting
T cells in response to the GAD65-specific peptides was detected in the PLN, ILN and spleen
of NOD mice vaccinated i.m. with pGAD65 versus untreated animals (Fig. 3). Furthermore
no significant increase in the frequency of IL-4 and IL-5 secreting T cells in the PLN or ILN
was detected in the pGAD65 i.m. group compared to untreated animals (Fig. 3). Interestingly,
a small but significant frequency of IL-4 secreting GAD65 peptide-specific T cells was also
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detected in the spleen of the i.m. pGAD65 vaccinated NOD mice; this response, however, was
markedly reduced compared to NOD mice treated with gene gun delivered pGAD65 (Fig. 3).
A predominate type 2-like GAD65 peptide-specific T cell response was detected in NOD mice
receiving gene gun delivered pGAD65. The frequency of IL-4 and IL-5 secreting T cells was
significantly increased in the PLN, ILN and spleen of the pGAD65 gene gun treated group
versus pGAD65 i.m. vaccinated and untreated NOD mice (Fig. 3). GAD65-specific T cells
secreting IFNγ were also induced via gene gun delivery of pGAD65, however, the frequency
of these type 1 effectors was reduced compared to the frequency of IL-4 (and to a lesser extent
IL-5) secreting T cells detected within a given tissue (Fig. 3). No significant increase was
detected in the frequency of GAD65 peptide-specific IL-10 secreting T cells relative to
medium-only controls in either of the pGAD65 treatment groups or in untreated NOD mice,
regardless of the tissue examined. Furthermore, GAD65-specific T cell reactivity was similar
between untreated NOD female mice and animals receiving pHEL by gene gun or i.m. delivery
(data not shown).
No significant increase was detected in the frequency of FoxP3-expressing CD4+CD25+ T
cells residing in the PLN, ILN and spleen of the two pGAD65 treatment groups compared to
untreated NOD mice (Fig. 4). In conclusion, these results demonstrate that whereas i.m.
injection of pGAD65 induces a type 1-like T cell response, gene gun delivery of pGAD65
elicits a predominately type 2-like response marked by a high frequency of GAD65 peptide-
specific IL-4 secreting T cells.
GAD65-specific IL-4 secreting CD4+ T cells are necessary to mediate the protective effect of
gene gun delivered pGAD65
The above findings suggested that suppression of β cell autoimmunity via gene gun delivered
pGAD65 was mediated by GAD65-specific CD4+ T cells secreting IL-4. To directly examine
this possibility, a co-adoptive transfer model of T1D was employed exploiting the use of NOD
mice lacking IL-4 expression (NOD.IL4null). Here 10 week-old wild-type NOD or
NOD.IL4null female mice received pGAD65 via gene gun. Three weeks after the final
treatment, CD4+ T cells were isolated from the pGAD65 treatment groups, and co-adoptively
transferred with diabetogenic splenocytes into groups of 5 NOD.scid mice. As demonstrated
in Fig. 5, the transfer of diabetes was significantly blocked by CD4+ T cells prepared from
pGAD65 gene gun vaccinated wild-type NOD mice compared to mice receiving diabetogenic
splenocytes-only (P<0.0053; Kaplan Meier Log Rank Test) (Fig. 5). In contrast, CD4+ T cells
prepared from pGAD65 gene gun vaccinated NOD.IL4null mice failed to block the transfer of
diabetes; no significant difference in the frequency and time of onset of diabetes was detected
in this group compared to NOD.scid mice receiving diabetogenic splenocytes-only (Fig. 5).
These data demonstrate that suppression of β cell autoimmunity by gene gun delivered
pGAD65 is dependent on GAD65-specific IL-4 secreting CD4+ T cells.
DISCUSSION
The key finding made in this study is that despite ongoing β cell autoimmunity, gene gun
delivered pGAD65 preferentially promotes a robust type 2 CD4+ T cell response that
significantly prevents the development of diabetes in NOD mice. This is in marked contrast to
i.m. injection of pGAD65 which induced a dominant type 1 GAD65-specific CD4+ T cell
response and failed to prevent diabetes in 10 week-old NOD female mice.
Our findings are consistent with previous studies demonstrating that antigen-encoding pDNA
delivered via gene gun typically induces type 2 immunity, whereas i.m. needle injection of
soluble pDNA promotes type 1 immunity [34;35]. Currently, the mechanisms which drive
these “default” T cell responses remain ill-defined. Interestingly, both gene gun and i.m.
vaccination of pGAD65 elicited high systemic levels of GAD65-IgFc protein based on serum
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levels in treated NOD mice (Fig. 1C). Although serum levels of GAD65Ig were greater in gene
gun treated NOD mice, protection did not correlate with systemic GAD65-IgFc concentrations
(Fig. 2C,D). These observations argue that the nature of the T cell response and suppression
of β cell autoimmunity are largely dependent on the site and mode of pDNA delivery. Indeed,
work by Escher and colleagues demonstrated that the onset of diabetes was delayed when 4
week-old NOD female mice received i.d. versus i.m. needle injections of pDNA encoding
human GAD65 [25]. In this study, however, i.d. needle injection failed to induce a significant
increase in GAD65-specific IL-4 secreting T cells despite the relatively non-stringent
conditions (e.g. lack of ongoing β cell autoimmunity) [25]. Our results in which a significant
frequency of GAD65-specific type 2 T cell reactivity was induced by gene gun delivery at a
late preclinical stage of T1D further underscores the potent effects of particle-delivery of pDNA
to the skin. The latter in part may be explained by the tolergenic properties of epidermal
Langerhans cells [37] that have been transfected by pDNA or which have endocytosed the
transgene encoded protein. Although not assessed in this study, the effect of gene gun-delivered
pGAD65 on islet-specific autoantibodies is of interest. Islet-specific autoantibodies are used
in the clinic to define the progression of β cell autoimmunity in at risk individuals [1]. Future
efforts will determine whether the delay in diabetes onset in NOD mice treated with gene gun-
delivered pGAD65 is reflected by changes in the level and/or isotype of serum islet-specific
autoantibodies.
The increased efficiency of transgene expression detected with gene gun versus i.m.
vaccination was another parameter favoring the use of particle-mediated delivery of pDNA
(Fig. 1B,C). Levels of protein expressed by pLUC or pGAD65 were increased by gene gun
delivery, despite using 50- to 100-fold less pDNA compared to i.m. injection (Fig. 1B,C). This
difference is likely attributed to the fact that pDNA coated on particles is directly delivered to
the cytoplasm and/or nucleus of cells residing in the skin [33]. Intramuscular vaccination of
pDNA in solution results in transfection of cells found at the site of injection as well as
systemically, but this process is nevertheless relatively inefficient.
Our results contrast findings made by Joussemet et al. [38] in which no significant induction
of type 2 T effectors or protection was observed when 3 week-old NOD female mice were
treated with gene gun delivered pDNA encoding full-length human GAD65. The major
difference between the respective studies is the cellular localization of the pDNA encoded
GAD65 protein. Full-length GAD65 is intracellularly expressed and presentation of GAD65
epitopes would be largely limited to professional antigen presenting cells (APC) residing in
the dermal region that have been directly transfected. Furthermore, intracellular GAD65 would
be preferentially processed and presented via the MHC class I pathway, which would reduce
the efficiency of CD4+ T cell activation. We have previously shown for example, that i.m.
delivery of pDNA encoding intracellular GAD65 to 4 wk-old NOD female mice had only a
minimal effect on GAD65-specific CD4+ T cell reactivity and disease progression [29]. On
the other hand, GAD65-IgFc is secreted by the transfected cells so that an increased number
of resident APC can endocytose the antigen, and preferentially present the GAD65-specific
epitopes via the MHC class II pathway and efficiently stimulate CD4+ T cells. Indeed other
studies have demonstrated that the magnitude and nature of T cell immunity induced by pDNA
vaccination is in part determined by the cellular localization of the protein (e.g. secreted versus
intracellular) [39].
Although gene gun delivered pGAD65 proved to be more effective than i.m. injection, a
significant number of NOD female mice nevertheless developed diabetes (Fig. 2A). This is
likely due to the frequency and/or type of GAD65-specific immunoregulatory T cells induced
following pGAD65 vaccination. For example, effective and long-term suppression of ongoing
β cell autoimmunity requires a relatively high frequency of diverse subsets of
immunoregulatory T effectors [26]. Protection mediated by gene gun delivered pGAD65 was
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dependent and limited to the induction of IL-4 secreting GAD65-specific CD4+ T cells (Fig.
3,Fig. 5). An increased frequency of IL-4 secreting insulin B chain-specific T cells was also
detected in the pGAD65 gene gun vaccinated NOD mice (data not shown) indicating “epitope-
spread” of type 2 immunoregulatory T effectors. Other types of immunoregulatory T cells such
as IL-10 secreting Tr1 cells or FoxP3-expressing CD4+CD25+ T cells (Fig. 4), however, were
not significantly increased following pGAD65 gene gun vaccination. Accordingly, the
magnitude and diversity of immunoregulatory T effectors can be effectively enhanced by co-
immunization with pDNA encoding other β cell autoantigens (e.g. insulin B chain) and/or anti-
inflammatory cytokines such as IL-4, IL-10 and TGFβ. Similarly, gene gun delivery of
autoantigen-encoding pDNA in a clinical setting may also require co-vaccination of
“adjuvants” to increase the frequency and types of immunoregulatory T effectors [40].
In summary, this study demonstrates that the route and mode of antigen-specific pDNA
vaccination are critical parameters for blocking β cell autoimmunity at a late preclinical stage
of T1D. Particle-delivered pDNA offers a promising approach to enhance the therapeutic
efficacy and safety of autoantigen-specific vaccination. These findings are especially relevant
in view of current efforts assessing antigen-specific pDNA vaccination for the treatment of
autoimmunity in the clinic [41;42].
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Figure 1. Increased transgene expression detected with gene gun versus i.m. delivery of pDNA
(A) Abdominal skin from untreated (left panel) or gene gun-treated (right panel) mice was
harvested, sectioned and stained with H&E. Arrows indicate the site of 1.6 µM gold particles
delivered by the gene gun. (B) Bioluminescence of NOD mice treated with pLUC by gene gun
or i.m. was measured at the site of injection. (C) Kinetics of systemic expression of GAD65-
IgFc transgene was assessed in 10 week-old NOD female mice treated at days 0, 7, 14, and 21
using gene gun or i.m. delivery; data represents the average ± SD of n=5 per group. Data are
representative of a minimum of 2 experiments. *P≤0.05, gene gun versus i.m. using Student’s
T test, n=5 per group.
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Figure 2. pGAD65 delivery via gene gun protects against diabetes
(A) Groups of 10 female NOD mice 10 weeks of age received 4 gene gun (GG) treatments of
pGAD65 or pHEL, or 4 i.m. injections of pGAD65 or pHEL or were left untreated. The
treatment groups were monitored for diabetes on a weekly basis. ***P=10−4, pGAD65 gene
gun versus pGAD65 i.m.; **P=0.005, pGAD65 gene gun versus untreated; *P=0.02, pGAD65
gene gun versus pHEL gene gun (Kaplan-Meier Log Rank Test). (B) The frequency of insulitis
was assessed via H&E staining of pancreatic sections prepared from nondiabetic 36 week-old
NOD female mice receiving via gene gun pGAD65 (n=5), or pHEL (n=2), or left untreated
(n=1); a minimum of 40 islets was examined per mouse. *P<10−3, >50% intra-insulitis for
pGAD65 versus pHEL or untreated mice (Chi Square). (C) Serum levels of GAD65-IgFc were
measured from pGAD65 gene gun treated NOD female mice in the above experiment. Dashed
and solid lines indicate NOD female mice that became diabetic or remained diabetes-free
during the course of the experiment, respectively. (D) The average serum levels of GAD65-
IgFc in pGAD65 gene gun treated mice depicted in panel C. Data are representative of a
minimum of 2 experiments.
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Figure 3. Gene gun induces GAD65-specific type 2 effector cells
Splenocytes (A), ILN (B), and PLN (C) were prepared from NOD female mice treated with
pGAD65 delivered via gene gun or i.m. injection or from untreated NOD mice and stimulated
with 40 µg/ml peptide. The frequency of GAD65 peptide-specific IL-4, IL-5, and IFN-γ,
secreting T cells were measured via ELISPOT. Data are representative of a minimum of 2
experiments. *P≤0.05 pGAD65 gene gun versus pGAD65 i.m.; **P≤0.05 pGAD65 gene gun
versus untreated; +P≤0.05 pGAD65 i.m. versus pGAD65 gene gun (One-way ANOVA).
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Figure 4. Gene gun and i.m. pGAD65 delivery had no effect on the frequency of FoxP3-expressing
CD4+CD25+ T cells
The frequency of FoxP3-expressing CD25+ T cells was determined by gating on CD3+ and
CD4+ T cells found in ILN, popliteal lymph nodes (POP), PLN and spleen (SPLN) of NOD
female mice treated at 10 weeks of age with pGAD65 delivered via gene gun or i.m. injection
or left untreated. Data are representative of 2 experiments.
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Figure 5. CD4+ T cells from pGAD65 gene gun treated NOD mice prevent diabetes in an IL-4
dependent manner
A mixture of diabetogenic splenocytes and CD4+ T cells purified from the spleens of wild type
NOD or NOD.IL-4null female mice treated with gene gun delivered pGAD65 were transferred
into groups of 5 NOD.scid mice (**P< 0.005, Kaplan Meier Log Rank Test comparing NOD
group to the NOD.IL-4null group).
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